drugset
drugset / Trial / NCT06386679

Amniotic Fluid Mesenchymal Stem Cells Developed for Chondrogenic Treatment (AFCC) Injection in Elderly Knee Osteoarthritis Patients

NCT06386679 ↗

Phase 1 Unknown 10 enrolled Siriraj Hospital
NaSingle-groupOpen-labelTreatment

Summary

Amniotic fluid mesenchymal stem cells developed for chondrogenic treatment (AFCC) are used to treat elderly patients suffering from knee osteoarthritis (OA). The injection reduces inflammation and promotes the recovery of knee function, leading to an improved quality of life.

Timeline

Start
2023-08-17
Primary completion
2023-11-23
Completion
2025-03

Drugs

EvaluationDrugModalityDoseRoute
Subject allogenic amniotic fluid mesenchymal stem cell Cell therapy 2e+07 cells Other

Indications

osteoarthritis, knee